Ernexa Therapeutics, Inc. (ERNA)
1.88
+0.05
(+2.73%)
USD |
NASDAQ |
Nov 06, 16:00
1.85
-0.03
(-1.60%)
After-Hours: 20:00
Ernexa Therapeutics Cash from Operations (Quarterly) : -4.152M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.152M |
| March 31, 2026 | -2.264M |
| December 31, 2025 | -1.148M |
| September 30, 2025 | -1.272M |
| June 30, 2025 | -2.532M |
| March 31, 2025 | -2.065M |
| December 31, 2024 | -3.545M |
| September 30, 2024 | -6.285M |
| June 30, 2024 | -2.259M |
| March 31, 2024 | -3.747M |
| December 31, 2023 | -4.661M |
| September 30, 2023 | -5.826M |
| June 30, 2023 | -3.872M |
| March 31, 2023 | -6.049M |
| December 31, 2022 | -5.435M |
| September 30, 2022 | -6.116M |
| June 30, 2022 | -3.993M |
| March 31, 2022 | -5.432M |
| December 31, 2021 | -6.832M |
| September 30, 2021 | -6.422M |
| June 30, 2021 | -6.804M |
| March 31, 2021 | -3.43M |
| December 31, 2020 | -1.638M |
| September 30, 2020 | -2.407M |
| June 30, 2020 | -2.184M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.873M |
| December 31, 2019 | 0.983M |
| September 30, 2019 | 0.422M |
| June 30, 2019 | 0.559M |
| March 31, 2019 | 0.78M |
| December 31, 2018 | 0.626M |
| September 30, 2018 | 0.50M |
| June 30, 2018 | 0.359M |
| March 31, 2018 | -0.12M |
| December 31, 2017 | -0.507M |
| September 30, 2017 | -1.75M |
| June 30, 2017 | 3.272M |
| March 31, 2017 | -0.466M |
| December 31, 2016 | 0.051M |
| September 30, 2016 | -0.041M |
| June 30, 2016 | 0.517M |
| March 31, 2016 | -0.504M |
| December 31, 2015 | -1.876M |
| September 30, 2015 | -1.088M |
| June 30, 2015 | -2.211M |
| March 31, 2015 | 0.995M |
| December 31, 2014 | -2.949M |
| September 30, 2014 | -1.446M |
| June 30, 2014 | -1.786M |
| March 31, 2014 | -0.204M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cerenome, Inc. | -7.132M |
| ACADIA Pharmaceuticals, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.003M |
| Cash from Financing (Quarterly) | 0.006M |
| Free Cash Flow | -8.878M |
| Free Cash Flow Per Share (Quarterly) | -3.512 |
| Free Cash Flow to Equity (Quarterly) | -4.115M |
| Free Cash Flow to Firm (Quarterly) | -4.155M |
| Free Cash Flow Yield | -721.5% |